NCT07078604 - A Cancer Vaccine (STEMVAC) in Combination With Chemotherapy for the Treatment of PD-L1 Negative Metastatic Triple-Negative Breast Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 1, 2025

Primary Completion Date

April 30, 2027

Study Completion Date

June 30, 2028

Conditions

Anatomic Stage IV Breast Cancer AJCC v8Metastatic Triple-Negative Breast Carcinoma

Interventions

BIOLOGICAL

CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine

Given ID

DRUG

Cisplatin

Given cisplatin

PROCEDURE

Computed Tomography

Undergo CT scans

PROCEDURE

Computed Tomography Assisted Biopsy

Undergo CT-guided biopsy

DRUG

Docetaxel

Given docetaxel

DRUG

Doxorubicin

Given doxorubicin

DRUG

Eribulin

Given eribulin

DRUG

Paclitaxel

Given paclitaxel

DRUG

Pegylated Liposomal Doxorubicin Hydrochloride

Given liposomal doxorubicin

BIOLOGICAL

Sargramostim

Given ID

PROCEDURE

Ultrasound-Guided Biopsy

Undergo ultrasound-guided biopsy

PROCEDURE

Biospecimen Collection

Undergo blood sample collection

DRUG

Carboplatin

Given carboplatin

PROCEDURE

Positron Emission Tomography (PET)

Undergo PET scan

Trial Locations (1)

98109

Fred Hutch/University of Washington Cancer Consortium, Seattle